|Bid||24.87 x 1000|
|Ask||24.88 x 1300|
|Day's Range||24.87 - 24.88|
|52 Week Range||24.74 - 26.93|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-4.11%|
|Beta (5Y Monthly)||N/A|
|Expense Ratio (net)||0.07%|
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, disinfectant use and dermatological conditions, and Microderm Technologies Ltd. announce that Dermodacyn® disinfectant has received import clearance as a medical device for Thailand with the help from Microderm’s partner VetSynova Co. Ltd., Thailand, and is now available online and in pharmacies and stores in Hong Kong and Thailand.
LOS ANGELES, CA / ACCESSWIRE / January 27, 2021 /The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. ("Sonoma" or "the Company") (NASDAQ:SNOA) for violations of the securities laws.
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public.